Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming events and other resources for investors.
A pipeline of possibility
Agios has a proven track record of leveraging our expertise in cellular metabolism to discover new therapeutic approaches and bring innovative medicines to patients in need.
Building on our core capabilities, we are advancing a robust pipeline focused on genetically defined diseases. At our core, we’re guided by a deep respect for science and a passion to change patients’ lives for the better.
Early Stage Clinical Development
Late Stage Clinical Development
Adult PK Deficiency
Adult Sickle Cell
For nearly 15 years, Agios has been committed to furthering the science of cellular metabolism to identify therapies for patients with unmet needs.
Our deep and differentiated understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together.